FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2289682804> ?p ?o ?g. }

• W2289682804 endingPage "25207" @default.
• W2289682804 startingPage "25194" @default.
• W2289682804 abstract "// Achinto Saha 1, 2, * , Jorge Blando 1, 2, * , Irina Fernandez 2, 3 , Kaoru Kiguchi 1, 2 , John DiGiovanni 1, 2 1 Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX 78723, USA 2 Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX 78723, USA 3 Stem Cell Transplantation Department, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA * These authors contributed equally to this work Correspondence to: John DiGiovanni, email: john.digiovanni@austin.utexas.edu Keywords: HMVP2 Cells, Hi-Myc mice, cancer stem cells, EMT, ventral prostate Received: November 05, 2015      Accepted: January 29, 2016      Published: February 20, 2016 ABSTRACT A cell line was established from ventral prostate (VP) tumors of one-year-old Hi-Myc mice. These cells, called HMVP2 cells, are Lin neg Sca-1 high CD49f high with high CD44 and CD29 expression and express CK14, Sca-1 and CD49f (but not CK8), suggesting basal-epithelial characteristics. Furthermore, HMVP2 cells form spheroids and both the cells and spheroids produce tumors in syngeneic mice. After four days of culture, HMVP2 spheroids underwent a gradual transition from Lin neg Sca-1 high CD49f high expression to Lin neg Sca-1 low CD49f low while a subpopulation of the cells retained the original Lin neg Sca-1 high CD49f high expression pattern. Additional cell subpopulations expressing Lin positive markers were also present suggesting further differentiation of HMVP2 spheroids. Two additional highly tumorigenic cell lines (HMVP2A1 and HMVP2A2) were isolated from HMVP2 cells after subsequent tumor formation in FVB/N mice. Concurrently, we also established cell lines from the VP of 6 months old Hi-Myc mice (named as HMVP1) and FVB/N mice (called NMVP) having less aggressive growth properties compared to the other three cell lines. AR expression was reduced in HMVP2 cells compared to NMVP and HMVP1 cells and almost absent in HMVP2A1 and HMVP2A2 cells. These cell lines will provide valuable tools for further mechanistic studies as well as preclinical studies to evaluate preventive and/or therapeutic agents for prostate cancer." @default.
• W2289682804 created "2016-06-24" @default.
• W2289682804 creator A5003201262 @default.
• W2289682804 creator A5005131670 @default.
• W2289682804 creator A5039241429 @default.
• W2289682804 creator A5065920207 @default.
• W2289682804 creator A5086525008 @default.
• W2289682804 date "2016-02-20" @default.
• W2289682804 modified "2023-09-23" @default.
• W2289682804 title "Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential<i>in vitro</i>and<i>in vivo</i>" @default.
• W2289682804 cites W1491670159 @default.
• W2289682804 cites W1821813067 @default.
• W2289682804 cites W1967323038 @default.
• W2289682804 cites W1976357851 @default.
• W2289682804 cites W1976419781 @default.
• W2289682804 cites W1981570197 @default.
• W2289682804 cites W1989272546 @default.
• W2289682804 cites W1993040599 @default.
• W2289682804 cites W1993376998 @default.
• W2289682804 cites W1994915831 @default.
• W2289682804 cites W1995097523 @default.
• W2289682804 cites W2003405179 @default.
• W2289682804 cites W2005658600 @default.
• W2289682804 cites W2017139179 @default.
• W2289682804 cites W2018439279 @default.
• W2289682804 cites W2020045401 @default.
• W2289682804 cites W2020124057 @default.
• W2289682804 cites W2020528447 @default.
• W2289682804 cites W2020762781 @default.
• W2289682804 cites W2033230341 @default.
• W2289682804 cites W2034182877 @default.
• W2289682804 cites W2039015433 @default.
• W2289682804 cites W2049700579 @default.
• W2289682804 cites W2051592780 @default.
• W2289682804 cites W2064293531 @default.
• W2289682804 cites W2066235353 @default.
• W2289682804 cites W2067206898 @default.
• W2289682804 cites W2069312908 @default.
• W2289682804 cites W2072713303 @default.
• W2289682804 cites W2077841029 @default.
• W2289682804 cites W2085212074 @default.
• W2289682804 cites W2085781596 @default.
• W2289682804 cites W2087390112 @default.
• W2289682804 cites W2088141769 @default.
• W2289682804 cites W2091443952 @default.
• W2289682804 cites W2102085111 @default.
• W2289682804 cites W2103177037 @default.
• W2289682804 cites W2108490782 @default.
• W2289682804 cites W2111441107 @default.
• W2289682804 cites W2119602224 @default.
• W2289682804 cites W2121982033 @default.
• W2289682804 cites W2122158568 @default.
• W2289682804 cites W2125819870 @default.
• W2289682804 cites W2127082045 @default.
• W2289682804 cites W2129781547 @default.
• W2289682804 cites W2136005507 @default.
• W2289682804 cites W2137782229 @default.
• W2289682804 cites W2138231163 @default.
• W2289682804 cites W2148416479 @default.
• W2289682804 cites W2150449422 @default.
• W2289682804 cites W2151784873 @default.
• W2289682804 cites W2153408949 @default.
• W2289682804 cites W2154079384 @default.
• W2289682804 cites W2156706402 @default.
• W2289682804 cites W2164942212 @default.
• W2289682804 cites W2166686631 @default.
• W2289682804 cites W2167277055 @default.
• W2289682804 cites W2314709323 @default.
• W2289682804 cites W2334632356 @default.
• W2289682804 cites W35348220 @default.
• W2289682804 cites W66989069 @default.
• W2289682804 doi "https://doi.org/10.18632/oncotarget.7535" @default.
• W2289682804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5041897" @default.
• W2289682804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26910370" @default.
• W2289682804 hasPublicationYear "2016" @default.
• W2289682804 type Work @default.
• W2289682804 sameAs 2289682804 @default.
• W2289682804 citedByCount "16" @default.
• W2289682804 countsByYear W22896828042016 @default.
• W2289682804 countsByYear W22896828042017 @default.
• W2289682804 countsByYear W22896828042018 @default.
• W2289682804 countsByYear W22896828042019 @default.
• W2289682804 countsByYear W22896828042020 @default.
• W2289682804 countsByYear W22896828042021 @default.
• W2289682804 countsByYear W22896828042022 @default.
• W2289682804 countsByYear W22896828042023 @default.
• W2289682804 crossrefType "journal-article" @default.
• W2289682804 hasAuthorship W2289682804A5003201262 @default.
• W2289682804 hasAuthorship W2289682804A5005131670 @default.
• W2289682804 hasAuthorship W2289682804A5039241429 @default.
• W2289682804 hasAuthorship W2289682804A5065920207 @default.
• W2289682804 hasAuthorship W2289682804A5086525008 @default.
• W2289682804 hasBestOaLocation W22896828041 @default.
• W2289682804 hasConcept C121608353 @default.
• W2289682804 hasConcept C126322002 @default.
• W2289682804 hasConcept C1491633281 @default.
• W2289682804 hasConcept C185592680 @default.
• W2289682804 hasConcept C2780192828 @default.

• next